Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

LOS ANGELES--(BUSINESS WIRE)---- $NTRA #NTRA--The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

AUSTIN, Texas, March 11, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, multi-center trial to measure the clinical impact of serial testing with Signatera in resectable CRC. Since its initial launch in January 2020, interest in the outcome of this trial has grown among oncologists nationwide, with a current target to enroll over 2,000 CRC patients across different stages of disease and to follow them for up to 5 years post surgery.

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

NTRA stock is flying higher after the company addressed Hindenburg's short report. Wall Street analysts are on Natera's side as well.

Why Is Natera (NTRA) Stock Up Today?

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

San Diego, California--(Newsfile Corp. - March 10, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Natera, Inc. (NASDAQ: NTRA) ("Natera" or the "Company"), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors' losses and whether they may be recovered under the federal securities laws.What if I purchased Natera common stock? If you...

(NTRA) News: Why did Natera Stock Drop? Contact Johnson Fistel

NEW YORK , March 10, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) resulting from allegations that Natera may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Natera securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Natera, Inc. Investors with Losses to Inquire About Class Action Investigation - NTRA

AUSTIN, Texas, March 9, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Mike Brophy, chief financial officer, will provide an update on a recent misleading short seller report in a special investor call. Conference Call Information: Date: March 10, 2022 Time: 4:00 a.m.

Natera to Host Special Investor Call in Response to Misleading Short Seller Report

Natera Inc (NASDAQ: NTRA) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock. Hindenburg Research stated, "Based on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online.

So What's Happening With Natera Shares?

Shares of Natera Inc. NTRA, -32.05% plummeted 32.9% in active afternoon trading Wednesday toward a 22-month low, enough to pace all of the Nasdaq's decliners, after noted short seller Hindenburg Research called the Texas-based genetic testing services company, "Pioneers in deceptive medical billing." Trading volume ballooned to 33.9 million shares, compared with the full-day average of less than 1 million shares.

Natera loses more than $1.7 billion in market cap, even after company calls Hindenburg report 'misleading'

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 p

The Law Offices of Frank R. Cruz Continues Its Investigation of Natera, Inc. (NTRA) on Behalf of Investors

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company  following a Hindenburg Research short report released the same morning criticizing Natera on "multiple.

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

Atlanta, Georgia--(Newsfile Corp. - March 9, 2022) - Holzer & Holzer, LLC is investigating whether Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) complied with federal securities laws. On March 9, 2022, Hindenburg Research issued a report alleging "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." Following this report, the Company's stock dropped. If you purchased Natera stock and suffered a loss on that...

SHAREHOLDER ALERT: Investigation of Natera (NTRA) Announced by Holzer & Holzer, LLC

NTRA stock has lost more than 35% following a short report by Hindenburg Research. The report alleges fraud, among other claims.

Why Is Natera (NTRA) Stock Down Today?

Natera, Inc. (NTRA) CEO Steve Chapman on Q4 2021 Results - Earnings Call Transcript

AUSTIN, Texas, Feb. 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated total revenues of $173.0 million in the fourth quarter of 2021 compared to $112.4 million in the fourth quarter of 2020, an increase of 53.9%.

Natera Reports Fourth Quarter and Full Year 2021 Financial Results

Natera, a clinic genetic testing company, has seen its sales rise from $212.5 million in FY '16 to $565 million on an LTM basis, a more than 2x rise.

Natera's Stellar Sales Growth Trend Makes It A Wise Bet

AUSTIN, Texas, Feb. 17, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2021, after the market close on February 24, 2022. Natera will host a conference call and webcast at 1:30 p.m.

Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out for

AUSTIN, Texas, Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study confirming strong performance of its Prospera donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection for kidney transplant patients. The study , published in Transplantation Proceedings, reports the real-world impact of dd-cfDNA on patient management in a multi-center, real-world clinical cohort, including 879 patients evaluated from 33 participating clinics.

Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test

NEW YORK--(BUSINESS WIRE)---- $NTRA--The law firm of Kirby McInerney LLP is investigating potential claims against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). The investigation concerns whether Natera has violated the federal securities laws and/or engaged in other unlawful business practices. Natera is a diagnostics company that develops and commercializes molecular testing services worldwide. On January 1, 2022, an article from the New York Times called into question the accuracy of certai

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Natera, Inc. (NTRA) Investors

AUSTIN, Texas, Jan. 22, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American Society of Clinical Oncology's 2022 Gastrointestinal Cancers Symposium (ASCO GI). The oral presentation included an updated analysis from the landmark CIRCULATE-Japan trial analyzing a cohort of colorectal cancer (CRC) patients.

Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Los Angeles, California--(Newsfile Corp. - January 21, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of the securities laws.The investigation focuses on whether t

Investigation Alert: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 20, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or mi

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

AUSTIN, Texas--(BUSINESS WIRE)---- $NTRA #22q--Largest prospective NIPT study shows the most common microdeletion can be detected non-invasively with a low false positive rate

Landmark SMART Study Demonstrates High Accuracy of Natera's Panorama® NIPT for 22q11.2 Deletion Screening

AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the company, along with its collaborators, will present new data on Natera's personalized, tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2022 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 20 – 22, 2022. Natera has two oral presentations and four collaborative poster presentations highlighting clinical findings on the performance of Signatera across colorectal (CRC), pancreatic and anal cancers.

News for Natera Stock (NTRA)